Polaris Partners Leads USD126m Series A for Singapore’s Tessa Therapeutics
Source(s): Tessa Therapeutics
Polaris Partners led a USD126m Series A for Tessa Therapeutics, a Singapore-based biotech developer for cancer treatments, with follow-on from Temasek, EDBI, Heliconia Capital and Heritas Capital. Read more